PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsPosaconazole
Noxafil(posaconazole)
Noxafil, Posaconazole (posaconazole) is a small molecule pharmaceutical. Posaconazole was first approved as Noxafil on 2005-10-25. It is used to treat mycoses and oral candidiasis in the USA. It has been approved in Europe to treat aspergillosis, candidiasis, coccidioidomycosis, and mycoses.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
stomatognathic diseasesD009057
Trade Name
FDA
EMA
Noxafil, Posaconazole (discontinued: Noxafil, Posaconazole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Posaconazole
Tradename
Company
Number
Date
Products
NOXAFILMerck & CoN-205596 RX2014-03-13
1 products, RLD, RS
NOXAFIL POWDERMIX KITMerck & CoN-214770 RX2021-05-31
1 products, RLD, RS
NOXAFILMerck & CoN-022003 RX2006-09-15
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
noxafilNew Drug Application2024-10-25
posaconazoleANDA2025-06-27
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration
Code
POSACONAZOLE, NOXAFIL, MERCK SHARP DOHME
2028-06-17ODE-355
2024-06-17I-881
2024-05-31NPP
POSACONAZOLE, NOXAFIL POWDERMIX KIT, MSD MERCK CO
2024-05-31NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Posaconazole, Noxafil, Merck Sharp Dohme
94935822033-02-27DP
90237902031-07-04DPU-1698, U-3160, U-3171
93582972031-06-24DPU-3160, U-3171
84100772029-03-13DP
97508222029-03-13DP
101179512029-03-13DP
ATC Codes
J: Antiinfectives for systemic use
J02: Antimycotics for systemic use
J02A: Antimycotics for systemic use
J02AC: Triazole and tetrazole derivatives
J02AC04: Posaconazole
HCPCS
No data
Clinical
Clinical Trials
104 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181B35-B495674628
Invasive fungal infectionsD0000727424242416
InfectionsD007239EFO_00005444324215
Communicable diseasesD0031414112210
AspergillosisD001228EFO_0007157B4412216
Invasive pulmonary aspergillosisD055744B44.01113
CandidiasisD002177B371113
NeutropeniaD009503D701113
Myeloid leukemia acuteD015470C92.0112
Myeloid leukemiaD007951C92112
Show 5 more
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnemiaD000740EFO_0004272D64.911
Aplastic anemiaD000741D61.911
PreleukemiaD01128911
SyndromeD01357711
Chagas diseaseD014355EFO_0008559B5711
LeukemiaD007938C9511
OnychomycosisD014009B35.111
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung transplantationD01604011
Covid-19D000086382U07.111
Respiratory tract infectionsD012141J06.911
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePosaconazole
INNposaconazole
Description
Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication.
Classification
Small molecule
Drug classsystemic antifungals (miconazole type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O
Identifiers
PDB
CAS-ID171228-49-2
RxCUI
ChEMBL IDCHEMBL1397
ChEBI ID64355
PubChem CID147912
DrugBankDB01263
UNII ID6TK1G07BHZ (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
Noxafil Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Posaconazole
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 12,380 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6,815 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use